Up to 84% of adult asthma patients present with type 2 inflammation, which can be both local and systemic. DUPIXENT targets both IL-4 and IL-13 signaling, two of the key sources of type 2 inflammation in asthma. The mechanism of dupilumab action has not been definitively established.^1,2,4,5